Lasmiditan

Lasmiditan
(IUPAC) ime
	2,4,6-Trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]benzamide
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	11610526
UNII	760I9WM792?
Hemijski podaci
Formula	C19H18F3N3O2
Mol. masa	377,36 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27) ; Key: XEDHVZKDSYZQBF-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Investigacioni
Način primene	Oralno, intravenozno

Lasmiditan (COL-144) je lek koji se ispituje za treatman akutne migrene. Njega je otkrila kompanija Eli Lilu, a u razvoju je od strane kompanije CoLucid Farmaceutikal. Klinička ispitivanja faze II za utvrđivanje doze su završena 2007 za intravenoznu^[3], i 2010. za oralnu primenu.^[4]

Mehanizam dejstva

Lasmiditan je agonist serotoninskog receptora koji se, poput neuspešnog LY-334,370, selektivno vezuje za 5-HT_1F receptor. Za brojne triptane je pokazano da deluju na ovom tipu receptora, ali je isto tako utvrđeno da je njihov afinitet za 5-HT_1B i 5-HT_1D odgovoran za njihovu antimigrensku aktivnost. Odsustvo afiniteta za te receptore može da proizvede manji broj nuspojava u pogledu vazokonstrikcije u odnosu sa triptanima.^[5] Jedan pregled iz 1998. je izneo da se takve nuspojave retko javljaju kod pacijenata koji koriste triptane.^[6]^[7]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Clinical Trials NCT00384774 A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine
↑ Clinical Trials NCT00883051 Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment
↑ „Molecule of the Month July 2010: Lasmiditan hydrochloride”. Prous Science. Arhivirano iz originala na datum 2011-07-28. Pristupljeno 3. 8. 2010.
↑ Dahlöf CG, Mathew N (1998). „Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern?”. Cephalalgia : an international journal of headache 18 (8): 539–45. DOI:10.1046/j.1468-2982.1998.1808539.x. PMID 9827245.
↑ Mutschler, Ernst; Gerd Geisslinger, Heyo K. Kroemer, Monika Schäfer-Korting (2001) (German). Arzneimittelwirkungen (8 izd.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. str. 265. ISBN 3-8047-1763-2.

Literatura

Mutschler, Ernst; Gerd Geisslinger, Heyo K. Kroemer, Monika Schäfer-Korting (2001) (German). Arzneimittelwirkungen (8 izd.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. str. 265. ISBN 3-8047-1763-2.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[NCT00384774-3] Clinical Trials NCT00384774 A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine

[NCT00883051-4] Clinical Trials NCT00883051 Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment

[Prous-5] „Molecule of the Month July 2010: Lasmiditan hydrochloride”. Prous Science. Arhivirano iz originala na datum 2011-07-28. Pristupljeno 3. 8. 2010.

[6] Dahlöf CG, Mathew N (1998). „Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern?”. Cephalalgia : an international journal of headache 18 (8): 539–45. DOI:10.1046/j.1468-2982.1998.1808539.x. PMID 9827245.

[Mutschler-7] Mutschler, Ernst; Gerd Geisslinger, Heyo K. Kroemer, Monika Schäfer-Korting (2001) (German). Arzneimittelwirkungen (8 izd.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. str. 265. ISBN 3-8047-1763-2.

[1]

[2]

[3]

[4]

[5]

[6]

[7]